https://doi.org/10.4081/monaldi.2022.2368
Interstitial nephritis secondary to treatment with pembrolizumab, a rare complication in two patients with lung adenocarcinoma
Submitted: July 5, 2022
Accepted: July 19, 2022
Published: July 28, 2022
Accepted: July 19, 2022
Abstract Views: 957
PDF: 367
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Immune checkpoint inhibitors (ICPi) have become nowadays one of the most widely prescribed anticancer treatments. Pembrolizumab is a highly selective monoclonal immunoglobulin approved as a first-line monotherapy treatment in adult patients with untreated advanced non-small cell lung cancer (NSCLC) with programmed cell death 1 (PD-L1) expression greater than 50% and lack of mutations. ICPi can precipitate immune-related adverse events. Data on the incidence and characteristics of nephrotoxicity from ICPi are limited and caused largely from small case series and oncologic studies. Two patients with a diagnosis of pulmonary adenocarcinoma, undergoing treatment with pembrolizumab who manifested interstitial nephritis secondary to this treatment, are presented below. The growing use of immunotherapy in the treatment of cancer imposes the physician's attention to possible adverse effects.
Gupta S, Short SAP, Sise ME, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer 2021;9:e003467.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158–68.
DOI: https://doi.org/10.1056/NEJMra1703481
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019;37:537-46.
DOI: https://doi.org/10.1200/JCO.18.00149
Espi M, Teuma C, Novel-Catin E, et al. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study. Eur J Cancer 2021;147:29–39.
DOI: https://doi.org/10.1016/j.ejca.2021.01.005
Meraz-Muñoz A, Amir E, Ng P, et al. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer 2020;8:e000467.
DOI: https://doi.org/10.1136/jitc-2019-000467
Izzedine H, Mathian A, Champiat S, et al. Renal toxicities associated with pembrolizumab. Clin Kidney J 2019;12:81–8.
DOI: https://doi.org/10.1093/ckj/sfy100
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol 2018;36:1714–68.
DOI: https://doi.org/10.1200/JCO.2017.77.6385
How to Cite
Gonçalves Pimenta, Diana Alexandra, Renata Carvalho, Raquel Pereira, Rui Rolo, and Lurdes Ferreira. 2022. “Interstitial Nephritis Secondary to Treatment With Pembrolizumab, a Rare Complication in Two Patients With Lung Adenocarcinoma”. Monaldi Archives for Chest Disease 93 (2). https://doi.org/10.4081/monaldi.2022.2368.
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Marika Werren, Roberto Copetti, Nicola Gaibazzi, Franco Giada, Andrea Faggiano, Chiara Ricci, Pompilio Faggiano, Choosing wisely in cardiology: Five proposals from the Italian Association for Cardiovascular Prevention and Rehabilitation , Monaldi Archives for Chest Disease: Vol. 89 No. 2 (2019)
- Carlo Iadevaia, Fabio Perrotta, Grazia Mazzeo, Francesco Saverio Cerqua, Gennaro Mazzarella, Salvatore Guarino, Roberto Parrella, Andrea Bianco, Incidental diagnosis of lung adenocarcinoma following coronavirus OC 43 severe pneumonia , Monaldi Archives for Chest Disease: Vol. 90 No. 3 (2020)
- Kamal Kant Sahu, Ajay Kumar Mishra, Kevin Martin, Iryna Chastain, COVID-19 and restrictive lung disease: A deadly combo to trip off the fine balance , Monaldi Archives for Chest Disease: Vol. 90 No. 2 (2020)
- Iffat Khanum, Fatima Samar, Yousuf Fatimah, Awan Safia, Aziz Adil, Habib Kiren, Nasir Nosheen, Mahmood Faisal, Jamil Bushra, Role of awake prone positioning in patients with moderate-to-severe COVID-19: an experience from a developing country , Monaldi Archives for Chest Disease: Vol. 91 No. 2 (2021)
- Abhenil Mittal, Aarushi Gupta, Ekta Dhamija, Adarsh Barwad, Sameer Rastogi, Sustained complete response on crizotinib in primary lung inflammatory myofibroblastic tumor - Case report and literature review , Monaldi Archives for Chest Disease: Vol. 91 No. 3 (2021)
- Tiziana Ciarambino, Elena Barbagelata, Graziamaria Corbi, Immacolata Ambrosino, Cecilia Politi, Franco Lavalle, Anna Ruggieri, Annamaria Moretti, Gender differences in vaccine therapy: where are we in COVID-19 pandemic? , Monaldi Archives for Chest Disease: Vol. 91 No. 4 (2021)
- Arturo Cesaro, Carmine Riccio, Paolo Calabrò, Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target , Monaldi Archives for Chest Disease: Vol. 91 No. 2 (2021)
- Rajesh Venkataram, Srividya Arjuna, Giridhar Belur Hosmane, Anirban Chakraborty, Quantitative analysis of cell-free DNA by droplet digital PCR reveals the presence of EGFR mutations in non-malignant lung pathologies , Monaldi Archives for Chest Disease: Vol. 91 No. 3 (2021)
- Michele Vitacca, Piero Ceriana, Bruno Balbi , Claudio Bruschi, Maria Aliani, Mauro Maniscalco, Francesco Fanfulla, Aldo Diasparra, Luigino Rizzello, Daniela Sereni, Antonio Spanevello, The respiratory rehabilitation Maugeri network service reconfiguration after 1 year of COVID-19 , Monaldi Archives for Chest Disease: Vol. 91 No. 4 (2021)
- Rajesh Venkataram, Vijith Shetty, Kishan Prasad, Sonam Kille, Teerthanath Srinivas, Anirban Chakraborty, Detection of clinically-relevant EGFR variations in de novo small cell lung carcinoma by droplet digital PCR , Monaldi Archives for Chest Disease: Vol. 93 No. 2 (2023)
You may also start an advanced similarity search for this article.
